Executive summary of the 14th HHT international scientific conference

IF 9.2 1区 医学 Q1 PERIPHERAL VASCULAR DISEASE Angiogenesis Pub Date : 2023-09-11 DOI:10.1007/s10456-023-09886-5
Roxana Ola, Josefien Hessels, Adrienne Hammill, Cassi Friday, Marianne Clancy, Hanny Al-Samkari, Stryder Meadows, Vivek Iyer, Rosemary Akhurst
{"title":"Executive summary of the 14th HHT international scientific conference","authors":"Roxana Ola,&nbsp;Josefien Hessels,&nbsp;Adrienne Hammill,&nbsp;Cassi Friday,&nbsp;Marianne Clancy,&nbsp;Hanny Al-Samkari,&nbsp;Stryder Meadows,&nbsp;Vivek Iyer,&nbsp;Rosemary Akhurst","doi":"10.1007/s10456-023-09886-5","DOIUrl":null,"url":null,"abstract":"<div><p>Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by small, dilated clustered vessels (telangiectasias) and by larger visceral arteriovenous malformations (AVMs), which directly connect the feeding arteries with the draining veins. These lesions are fragile, prone to rupture, and lead to recurrent epistaxis and/or internal hemorrhage among other complications. Germline heterozygous loss-of-function (LOF) mutations in Bone Morphogenic Protein 9 (BMP9) and BMP10 signaling pathway genes (endoglin-<i>ENG</i>, activin like kinase 1 <i>ACVRL1</i> aka <i>ALK1,</i> and <i>SMAD4</i>) cause different subtypes of HHT (HHT1, HHT2 and HHT-juvenile polyposis (JP)) and have a worldwide combined incidence of about 1:5000. Expert clinicians and international scientists gathered in Cascais, Portugal from September 29th to October 2<sup>nd</sup>, 2022 to present the latest scientific research in the HHT field and novel treatment strategies for people living with HHT. During the largest HHT scientific conference yet, participants included 293 in person and 46 virtually. An impressive 209 abstracts were accepted to the meeting and 59 were selected for oral presentations. The remaining 150 abstracts were presented during judged poster sessions. This review article summarizes the basic and clinical abstracts selected as oral presentations with their new observations and discoveries as well as surrounding discussion and debate. Two discussion-based workshops were also held during the conference, each focusing on mechanisms and clinical perspectives in either AVM formation and progression or current and future therapies for HHT. Our hope is that this paper will represent the current progress and the remaining unanswered questions surrounding HHT, in order to serve as an update for those within the field and an invitation to those scientists and clinicians as yet outside of the field of HHT.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":null,"pages":null},"PeriodicalIF":9.2000,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10456-023-09886-5.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiogenesis","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s10456-023-09886-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by small, dilated clustered vessels (telangiectasias) and by larger visceral arteriovenous malformations (AVMs), which directly connect the feeding arteries with the draining veins. These lesions are fragile, prone to rupture, and lead to recurrent epistaxis and/or internal hemorrhage among other complications. Germline heterozygous loss-of-function (LOF) mutations in Bone Morphogenic Protein 9 (BMP9) and BMP10 signaling pathway genes (endoglin-ENG, activin like kinase 1 ACVRL1 aka ALK1, and SMAD4) cause different subtypes of HHT (HHT1, HHT2 and HHT-juvenile polyposis (JP)) and have a worldwide combined incidence of about 1:5000. Expert clinicians and international scientists gathered in Cascais, Portugal from September 29th to October 2nd, 2022 to present the latest scientific research in the HHT field and novel treatment strategies for people living with HHT. During the largest HHT scientific conference yet, participants included 293 in person and 46 virtually. An impressive 209 abstracts were accepted to the meeting and 59 were selected for oral presentations. The remaining 150 abstracts were presented during judged poster sessions. This review article summarizes the basic and clinical abstracts selected as oral presentations with their new observations and discoveries as well as surrounding discussion and debate. Two discussion-based workshops were also held during the conference, each focusing on mechanisms and clinical perspectives in either AVM formation and progression or current and future therapies for HHT. Our hope is that this paper will represent the current progress and the remaining unanswered questions surrounding HHT, in order to serve as an update for those within the field and an invitation to those scientists and clinicians as yet outside of the field of HHT.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
第十四届HHT国际科学会议执行摘要。
遗传性出血性毛细血管扩张症(HHT)是一种常染色体显性遗传性血管疾病,其特征是小型扩张的聚集性血管(毛细血管扩张症)和较大的内脏动静脉畸形(AVM),这些畸形直接连接供血动脉和引流静脉。这些病变很脆弱,容易破裂,并导致复发性鼻出血和/或内出血等并发症。骨形成蛋白9(BMP9)和BMP10信号通路基因(endoglin ENG、激活素样激酶1 ACVRL1 aka ALK1和SMAD4)中的种系杂合功能丧失(LOF)突变导致不同亚型的HHT(HHT1、HHT2和HHT幼年息肉病(JP)),在全球范围内的综合发病率约为1:5000。2022年9月29日至10月2日,专家临床医生和国际科学家聚集在葡萄牙卡斯凯,介绍HHT领域的最新科学研究以及HHT患者的新治疗策略。在迄今为止规模最大的HHT科学会议上,与会者包括293人,46人。会议接受了令人印象深刻的209篇摘要,并选出59篇进行口头陈述。其余150篇摘要是在经过评委的海报会议上发表的。这篇综述文章总结了被选为口头陈述的基础和临床摘要,以及它们的新观察和发现,以及周围的讨论和辩论。会议期间还举办了两次基于讨论的研讨会,每一次都侧重于AVM形成和进展的机制和临床观点,或HHT的当前和未来治疗方法。我们希望这篇论文将代表当前的进展和围绕HHT的剩余未回答的问题,以便为该领域的研究人员提供最新信息,并邀请那些尚未进入HHT领域的科学家和临床医生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Angiogenesis
Angiogenesis PERIPHERAL VASCULAR DISEASE-
CiteScore
21.90
自引率
8.20%
发文量
37
审稿时长
6-12 weeks
期刊介绍: Angiogenesis, a renowned international journal, seeks to publish high-quality original articles and reviews on the cellular and molecular mechanisms governing angiogenesis in both normal and pathological conditions. By serving as a primary platform for swift communication within the field of angiogenesis research, this multidisciplinary journal showcases pioneering experimental studies utilizing molecular techniques, in vitro methods, animal models, and clinical investigations into angiogenic diseases. Furthermore, Angiogenesis sheds light on cutting-edge therapeutic strategies for promoting or inhibiting angiogenesis, while also highlighting fresh markers and techniques for disease diagnosis and prognosis.
期刊最新文献
Correction: Mitochondrial control of hypoxia-induced pathological retinal angiogenesis. Angiogenesis is limited by LIC1-mediated lysosomal trafficking. Similarities and differences between brain and skin GNAQ p.R183Q driven capillary malformations. Inflammasome activation aggravates choroidal neovascularization. Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1